Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

Iovance Biotherapeutics (NASDAQ:IOVA) is preparing to seek a lung cancer indication for its cell therapy AMTAGVI in 2027 while expanding its melanoma treatment network and advancing studies in earlier-stage melanoma and rare sarcomas, executives said at a Jefferies event.

The company reported approximately $122 million in third-quarter U.S. sales of AMTAGVI and PROLEUKIN, bringing year-to-date revenue to $292 million, Chief Commercial Officer Dan Kirby and Chief Financial Officer Corleen Roche said. That compares with $264 million for all of 2025. Iovance raised its 2026 revenue guidance to $410 million to $420 million.

Roche said the company felt good about its fourth-quarter outlook but had not decided when to provide 2027 guidance. Iovance has not typically preannounced results, she added.

Melanoma launch and pricing

AMTAGVI, a one-time tumor-infiltrating lymphocyte, or TIL, therapy, received its initial U.S. approval in February 2024. Kirby said the company is focused on expanding physician awareness, increasing referrals and opening more authorized treatment centers. Iovance is on track to meet or exceed its goal of at least 110 centers by year-end, he said.

Kirby estimated the U.S. market for second-line and later metastatic melanoma treatment at about 8,500 patients annually. He said the potential market would rise to more than 22,000 patients with a first-line indication.

Iovance has notified treatment centers and payers that AMTAGVI’s price will increase 9% and PROLEUKIN’s price will rise 7%, effective Jan. 1, 2027, Kirby said.

AMTAGVI is approved in the U.S., Canada and Australia, with decisions expected in the first quarter in Switzerland and the U.K., Kirby said. The company is also working toward a European Union resubmission. He said Iovance’s Philadelphia facility can supply international markets and has room to expand production without opening another site in the near term.

Lung cancer filing plans

Iovance expects to submit a supplemental biologics license application in 2027 for a broad second-line lung cancer population, executives said. Brian Gastman, executive vice president of translational medicine, said the company is close to completing enrollment of 80 patients in its registrational IOV-LUN-202 trial and plans to present a fuller data set at a major medical meeting.

Jefferies analyst Andrew Tsai cited an updated 25% overall response rate among 69 patients. Gastman said response rates had remained consistent across data cuts, while the most recent duration-of-response data were too immature to assess.

Chief Medical Officer Noah Berkowitz said safety had improved after a change to the lymphodepletion regimen, including a reduction in grade 4 and 5 treatment-related adverse events. He said the company had not provided a specific breakdown of those events.

Iovance is also pursuing the POSITILITY cohort in a biomarker-defined subgroup and plans to start a separate first-line lung study, OPTILISM, in 2027. Berkowitz said the company has not provided a timeline for data from either study and views a potential filing for the subgroup as subsequent to the broader lung application.

Other studies and financial targets

In melanoma, the phase 3 TILVANCE-301 trial is intended to support confirmation of AMTAGVI’s existing accelerated approval and a potential first-line indication, Gastman said. Iovance has not provided a data-readout timeline.

The company is also beginning SARATOGA, an 80-patient study in two soft tissue sarcoma types. Berkowitz said an investigator-initiated study previously showed a response rate above 50%, while Kirby said the new study was off to a fast start.

Roche said third-quarter gross margin reached 60%, bringing the year-to-date figure to 54%. She expects longer-term improvement, although not necessarily in every quarter, and reiterated a goal of at least 70% without providing a timeframe. Iovance ended its latest reported quarter with $382 million, she said.

About Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.